ADMA Biologics ADMA Excess tax benefits associated with employee equity plans (in percent)

Excess tax benefits associated with employee equity plans (in percent) at other companies

Charles River LaboratoriesCRL

2.6%+2.5pp

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Market cap$2.02B-54.5%

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is ADMA Biologics's excess tax benefits associated with employee equity plans (in percent)?: ADMA Biologics (ADMA) reported excess tax benefits associated with employee equity plans (in percent) of -4.3% in Q4 2025.
What does excess tax benefits associated with employee equity plans (in percent) mean?: The percentage point impact on the effective tax rate resulting from excess tax benefits derived from share-based compensation. It measures the relative efficiency of the company's equity incentive programs in reducing the overall tax burden.